Rosmawati Mohamed

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1242476/publications.pdf

Version: 2024-02-01

44 papers 1,733 citations

16 h-index 276539 41 g-index

46 all docs

46 docs citations

46 times ranked

2576 citing authors

#	Article	IF	CITATIONS
1	Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International, 2012, 6, 531-561.	1.9	874
2	A multi-ethnic study of a PNPLA3 gene variant and its association with disease severity in non-alcoholic fatty liver disease. Human Genetics, 2012, 131, 1145-1152.	1.8	84
3	Sofosbuvir–velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 127-134.	3.7	83
4	Peripheral loss of <scp>CD</scp> 8 ⁺ <scp>CD</scp> 161 ⁺⁺ <scp>TCRV</scp> α7·2 ⁺ mucosalâ€associated invariant T cells in chronic hepatitis C virusâ€infected patients. European Journal of Clinical Investigation, 2016, 46, 170-180.	1.7	75
5	Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. The Lancet Gastroenterology and Hepatology, 2016, 1, 248-255.	3.7	54
6	Practical difficulties in the management of hepatitis B in the Asia-Pacific region. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 958-969.	1.4	51
7	Knowledge, attitudes and practices among people with chronic hepatitis B attending a hepatology clinic in Malaysia: A cross sectional study. BMC Public Health, 2012, 12, 601.	1.2	45
8	An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. Journal of Gastroenterology, 2020, 55, 811-823.	2.3	41
9	Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis. BMC Infectious Diseases, 2014, 14, 564.	1.3	31
10	Genome-Wide Analysis of Copy Number Variation Identifies Candidate Gene Loci Associated with the Progression of Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e95604.	1.1	30
11	Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. Cells, 2018, 7, 165.	1.8	27
12	CD8+ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. Cellular Immunology, 2017, 313, 1-9.	1.4	22
13	Universal Primers for Detection and Sequencing of Hepatitis B Virus Genomes across Genotypes A to G. Journal of Clinical Microbiology, 2015, 53, 1831-1835.	1.8	21
14	Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia. PLoS ONE, 2015, 10, e0128091.	1.1	21
15	Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease. Frontiers in Pediatrics, 2019, 7, 491.	0.9	20
16	Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort. Clinical and Molecular Hepatology, 2021, 27, 486-498.	4.5	20
17	Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 1297-1305.	1.0	19
18	A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs. Value in Health Regional Issues, 2019, 18, 112-120.	0.5	18

#	Article	IF	CITATIONS
19	Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: A randomized trial. Journal of Clinical Virology, 2014, 61, 509-516.	1.6	14
20	Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 161-166.	0.4	14
21	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. Kidney International Reports, 2020, 5, 1129-1138.	0.4	14
22	Interleukin-6 gene variants are associated with reduced risk of chronicity in hepatitis B virus infection in a Malaysian population. Biomedical Reports, 2018, 9, 213-220.	0.9	13
23	Conflicting reports on the role of the glycemic effect of Catha edulis (Khat): A systematic review and meta-analysis. Journal of Ethnopharmacology, 2016, 186, 30-43.	2.0	12
24	Hepatocellular Carcinoma in Malaysia and Its Changing Trend. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 54-56.	0.1	12
25	Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040. Applied Health Economics and Health Policy, 2018, 16, 847-857.	1.0	11
26	Risk factors of nonalcoholic fatty liver disease in lean body mass population: A systematic review and metaâ€analysis. JGH Open, 2021, 5, 1236-1249.	0.7	11
27	Comparative expression of pro-inflammatory and apoptotic biosignatures in chronic HBV-infected patients with and without liver cirrhosis. Microbial Pathogenesis, 2021, 161, 105231.	1.3	9
28	Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resourceâ€imited settings. Journal of Viral Hepatitis, 2020, 27, 466-475.	1.0	8
29	Hepatitis Screening and Treatment Campaign in Malaysia- Validation of Low-cost Point of Care Screening Tests and Nucleic Acid Tests for Hepatitis B and C. Euroasian Journal of Hepato-gastroenterology, 2018, 8, 101-107.	0.1	7
30	Copy number variation in exportin-4 (XPO4) gene and its association with histological severity of non-alcoholic fatty liver disease. Scientific Reports, 2015, 5, 13306.	1.6	6
31	Novel Genetic Variants of Hepatitis B Virus in Fulminant Hepatitis. Journal of Pathogens, 2017, 2017, 1-6.	0.9	6
32	Hepatitis C core antigen testing to diagnose active hepatitis C infection among haemodialysis patients. BMC Nephrology, 2020, 21, 480.	0.8	6
33	Contextual and individual factors associated with knowledge, awareness and attitude on liver diseases: A largeâ€scale Asian study. Journal of Viral Hepatitis, 2022, 29, 156-170.	1.0	6
34	Estimating the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method. Substance Use and Misuse, 2020, 55, 871-877.	0.7	4
35	Chronic Viral Hepatitis in Malaysia: "Where are we now?― Euroasian Journal of Hepato-gastroenterology, 2017, 7, 65-67.	0.1	4
36	Increased Coffee Intake Reduces Circulating HBV DNA and HBsAg Levels in HBeAg-Negative Infection: A Cohort Study. Viruses, 2019, 11, 808.	1.5	3

3

#	Article	IF	CITATIONS
37	IDDF2018-ABS-0112â€Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1–6 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial. , 2018, , .		2
38	Stopping Therapy in HBeAg Negative Disease. Current Hepatitis Reports, 2013, 12, 105-111.	0.3	1
39	Primer and probe conservation issue in the quantification of hepatitis B virus DNA. Reviews in Medical Virology, 2021, 31, e2182.	3.9	1
40	Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications. Nephrology, 2021, 26, 463-470.	0.7	1
41	Hepatitis C elimination by 2030 in Malaysia: an achievable goal?. Journal of Virus Eradication, 2019, 5, 253.	0.3	1
42	MAIT cells in hepatitis B virus infection – Diplomatic front-runners in the fight against HBV disease. Critical Reviews in Immunology, 2021, 41, 1-16.	1.0	1
43	Allele HLAâ€ÐQB1*06 reduces fibrosis score in patients with nonâ€alcoholic fatty liver disease. Hepatology Research, 2020, 50, 947-954.	1.8	O
44	Association of deleted in liver cancer-1 gene polymorphism with increased risk of chronicity of disease among Malaysian patients with hepatitis B infection. Pharmacogenetics and Genomics, 2021, Publish Ahead of Print, 185-190.	0.7	0